Pexidartinib

(Turalio®)

Turalio®

Drug updated on 11/29/2023

Dosage FormCapsule (oral; 200 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Product Monograph / Prescribing Information

Document TitleYearSource
Turalio (pexidartinib) Prescribing Information.2022Daiichi Sankyo, Inc., Basking Ridge, NJ

Randomized Controlled Trials


Sex Distribution:

F:59%
M:41%
120Subjects

Year:

2023

Source:Clinical Orthopaedics and Related Research


Sex Distribution:

F:59%
M:41%
120Subjects

Year:

2020

Source:The Lancet